Integrated genome-wide DMA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1417-1427

  Etemadmoghadam, Dariush ^a,b   Defazio, Anna ^c   Beroukhim, Rameen ^d   Mermel, Craig ^d   George, Joshy ^a,b   Getz, Gad ^d   Tothiil, Richard ^a   Okamoto, Aikou ^f   Raeder, Maria B ^g   Harnett, Paul ^c   Lade, Stephen ^a   Akslen, Lars A ^h   Tinker, Anna V ^a   Locandro, Bianca ^a   Aisop, Kathryn ^a   Chiew, Yoke Eng ^c   Traficante, Nadia ^a   Fereday, Sian ^a   Johnson, Daryl ^a   Fox, Stephen ^a   Sellers, William ^e   Urashima, Mitsuyoshi ^f   Salvesen, Helga B ^g,i   Meyerson, Matthew ^d   Bowtell, David ^a,b   more..

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR 1; GENE PRODUCT; MUCIN 1; MYC PROTEIN; PROTEIN EVI1; PROTEIN MDS1; PROTEIN PRKCI; PROTEIN RAB25; PROTEIN RSF1; PROTEIN ZNF217; SOMATOMEDIN B RECEPTOR; STEROID RECEPTOR COACTIVATOR 3; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; CCNE1 PROTEIN, HUMAN; HISTONE ACETYLTRANSFERASE; KI 67 ANTIGEN; NUCLEAR RECEPTOR COACTIVATOR 3; ONCOPROTEIN; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME 19Q; CHROMOSOME 20Q; CHROMOSOME 22Q; CHROMOSOME 2Q; CHROMOSOME 5P; CHROMOSOME 6P; CHROMOSOME DELETION; CHROMOSOME MAP; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; DRUG TREATMENT FAILURE; EXTRACELLULAR MATRIX; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; DRUG RESISTANCE; GENE DELETION; GENE DOSAGE; GENETICS; MIDDLE AGED; OVARY TUMOR; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN E; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; HISTONE ACETYLTRANSFERASES; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANS-ACTIVATORS;

EID: 63149190291     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1564     Document Type: Article

References (50)

1. Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer -treatment at first diagnosis. Lancet Oncol 2002;3:529-36.
2. Bookman MA. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer 2005;15 Suppl 3:212-20.
3. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84.
4. Pinkel D, Albertson DG. Comparative genomic hybridization. Annu Rev Genomics Hum Genet 2005;6: 331-54.
5. Partheen K, Levan K, Osterberg L, Helou K, Horvath G. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and sub- stage. Genes Chromosomes Cancer 2004;40:342-8.
6. Staebler A, Karberg B, Behm J, et al. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer 2006;45:905-17.
7. Kim SW, Kim JW, Kim YT, et al. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: potential predictive markers of chemoresist- ant disease. Genes Chromosomes Cancer 2007;46: 1 -9.
8. Bemardini M, Lee CH, Beheshti B, et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 2005;7:603-13.
9. Birrer MJ, Johnson ME, Hao K, et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 2007;25: 2281 -7.
10. Osterberg L, Levan K, Partheen K, Helou K, Horvath G. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cancer Genet Cytogenet 2005;163:144-50.
11. Suzuki S, Moore DH, Ginzinger DG, et al. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 2000;60:5382-5.
12. Nanjundan M, Nakayama Y, Cheng KW, et al. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 2007; 67:3074 -84.
13. Mayr D, Kanitz V, Anderegg B, et al. Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 2006;126:101 -9.
14. Farley J, Smith LM, Darcy KM, et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res 2003;63:1235-41.
15. Eder AM, Sui X, Rosen DG, et al. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:12519-24.
16. Shih le M, Sheu JJ, Santillan A, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A 2005; 102:14004-9.
17. Cheng KW, Lahad JP, Kuo WL, et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004;10:1251 -6. Epub 2004 Oct 24.
18. Kato H, Arakawa A, Suzumori K, Kataoka N.Young SR. FISH analysis of BRCA1 copy number in paraffin- embedded ovarian cancer tissue samples. Exp Mol Pathol 2004;76:138-42.
19. Lassus H, Leminen A, Vayrynen A, et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004;92:31 -9.
20. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
21. Takano M, Fujii K, KitaT, KikuchiY, Uchida K. Ampli- con profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer. Oncol Rep 2004;12:1177-82.
22. Makhija S, Sit A, Edwards R, et al. Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. Gynecol Oncol 2003;90:3-9.
23. Peiro G, Diebold J, Lohrs U. CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression. Am J Clin Pathol 2002;118:922-9.
24. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol 1990;38:340-2.
25. Tothill RW.Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. In press.
26. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage NIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103:559-64.
27. Rustin GJ, Nelstrop AE.Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow- up according to CA125: a NorthThames Ovary Group Study. Ann Oncol 1996;7:361 -4.
28. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer In- tergroup. J Natl Cancer Inst 2000;92:1534-5.
29. Matsuzaki H, Dong S, Loi H, et al. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. Nat Methods 2004;1:109-11.
30. Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007;104:20007-12.
31. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-86.
32. Mi H, Guo N, Kejariwal A, Thomas PD. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res 2007;35:0247- 52.
33. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006;6:99-106.
34. Snijders AM, Nowee ME, Fridlyand J, et al. Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene 2003;22:4281 -6.
35. Park JT, Li M, Nakayama K, et al. Notch3 gene amplification in ovarian cancer. Cancer Res 2006;66: 6312-8.
36. Paige AJ, Taylor KJ, Taylor C, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A 2001;98:11417-22.
37. Gorringe KL, Jacobs S.Thompson ER, et al. High- resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 2007;13:4731-9.
38. Tanner MM, Grenman S, Koul A, et al. Frequent amplification of chromosomal region 20q12-13 in ovarian cancer. Clin Cancer Res 2000;6:1833-9.
39. Zhao X, Li C, Paez JG, et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004;64:3060-71.
40. Zhao C, Yasui K, Lee CJ, et al. Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 2003;98: 18-23.
41. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene 2005;24:2776-86.
42. Geng Y Lee YM, Welcker M, et al. Kinase-indepen- dent function of cyclin E. Mol Cell 2007;25:127-39.
43. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005;5:516-25.
44. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 2004;23: 2648-57.
45. Kolfschoten GM, Hulscher TM, Pinedo HM, Boven E. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Br J Cancer 2000; 83:921 -7.
46. Jazaeri AA, Awtrey CS, Chandramouli GV, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005;11:6300-10.
47. Chia W, Prokopenko SN. Cyclin E at the centre of an identity crisis. Nat Cell Biol 2005;7:3-5.
48. Chia W, Somers WG. Wang H. Drosophila neuroblast asymmetric divisions: cell cycle regulators, asymmetric protein localization, and tumorigenesis. J Cell Biol 2008;180:267-72.
49. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, TIsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-11.
50. Sherman-Baust CA, Weeraratna AT, Rangel LB, et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003; 3:377-86.